AgeingVitC-AgingNCT06794255
Exploratory Study on the Role of Vitamin C in Promoting Health in Middle-Aged and Elderly Adults
A study testing Vitamin C in people with Ageing, run by Peking University Third Hospital at 3 sites in China.
Trial summary
The purpose of this clinical trial is to understand whether oral vitamin C can help delay the aging of middle-aged and elderly individuals, search for sensitive biomarkers of human aging, and provide new paradigms and scientific guidance for aging intervention with small molecule drugs. Read more about this study
- Who is it for?
- Ages 18 to 70 yearsHealthy volunteers can take part
- Conditions the study is for
- Ageing
- What is being tested?
- Vitamin C
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 400 participants
- Where
- 3 sitesChina
- Study dates
- 2 Apr 2025to 30 Jan 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 70 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Age: 55-65 years (for the experimental and control groups) or 18-70 years (for the baseline control group assessing aging changes).
- Health Status: Deemed to be in good health based on medical evaluation, including medical history, physical examination, laboratory tests, and cardiac monitoring.
- Weight: BMI within the range of 18.5-28 kg/m².
- Informed Consent: Capable of signing the informed consent form and complying with the requirements and restrictions outlined in the study protocol.
Who cannot join
- Disease Status:Uncontrolled medical conditions or any disease that, in the investigator's opinion, may pose an inappropriate risk or contraindication or interfere with the study's objectives, conduct, or evaluation.Severe chronic or acute diseases (e.g., cancer, heart failure, renal insufficiency, COPD, diabetes, active liver disease, metabolic acidosis, poorly controlled hypertension, epilepsy, recent cardiovascular events, inflammatory bowel disease, neurological disorders, infectious diseases, severe autoimmune diseases, etc.).
- Weight: BMI < 18.5 or BMI > 28.
- Substance/Alcohol Abuse: Ongoing alcohol or drug abuse, or excessive alcohol consumption.
- Medical History: History of gastrointestinal diseases, hyperuricemia, kidney or urinary tract stones, glucose-6-phosphate dehydrogenase deficiency, or paroxysmal nocturnal hemoglobinuria.
- Allergy: Allergy to vitamin C or any component of its formulation.
- Recent Medication Use: Use of high-dose vitamin C, vitamin E, low-dose aspirin, acarbose, metformin, NMN/NR, or other anti-aging/weight-loss drugs within the past 3 months.
Show all 9Show fewer
- Informed Consent: Inability to provide informed consent.
- Other: Any physical condition that, in the investigator's opinion, may adversely affect the study process or outcomes.
- Clinical Research Participation: Participation in any other clinical research within 3 months prior to screening or during the study period, or receipt of chemotherapy, radiotherapy, biologic therapy, small-molecule therapeutic agents, or investigational drugs, with incomplete recovery from related side effects (excluding alopecia or potential neuropathy).
Trial locations and contacts
3 sites in 1 country. Contact the study team or a site near you to ask about taking part.
China3 sites, 3 recruiting
- Enrolling by invitation
Peking University Third Hospital
Beijing, 100191
- Recruiting
The first affiliated hospital of Nanchang University
Nanchang, Jiangxi, 330006
Wei Zhang, 15797738055, zhangweiliuxin@163.com
- Recruiting
People's Hospital of Quzhou
Quzhou, Zhejiang, 324000
Feng Zhang, felix.f.zhang@outlook.com
About this study
Official title: Randomized Controlled Trial on Vitamin C Supolementation for HealthRegulation in Middle-Aged and Elderly Adults
The purpose of this clinical trial is to understand whether oral vitamin C can help delay the aging of middle-aged and elderly individuals, search for sensitive biomarkers of human aging, and provide new paradigms and scientific guidance for aging intervention with small molecule drugs. The main questions it aims to answer are as follows:
- Can oral vitamin C effectively improve the aging-related indicators?
- What is the safety of participants when taking vitamin C supplements?
Read more
Researchers will compare vitamin C with a placebo to observe whether vitamin C is effective in intervening in the aging of middle-aged and elderly individuals. Participants need to:
- Take 2 tablets (250mg/tablet) of vitamin C or placebo after breakfast and dinner every day for 12 consecutive months;
- Go to the designated place for a face-to-face follow-up every 6 months and receive a telephone follow-up every 2 months, and pick up subsequent drugs during the follow-up;
- Honestly inform the medication situation during each follow-up;
- Report any discomfort or adverse reactions that occur during the treatment process to the researchers;
- Fill in a questionnaire about their own health status during each follow-up;
- After 6 months and 12 months of intervention, conduct a comprehensive health examination as required, including blood tests and other items.
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Vitamin CDietary supplement
Participants swallow synthetic vitamin C tablets 500mg with water, twice a day.
PlaceboOther
Participants swallow tablets with the same texture, flavor, and appearance as the experimental group 500mg with water, twice a day.
| Study group | Role | What they receive |
|---|---|---|
| Vitamin C | Experimental | Participants will take the synthetic vitamin C twice a day, 500mg per time Receives: Dietary Supplement: Vitamin C |
| Placebo | Placebo comparator | Participants will take tablets with the same texture, flavor, and appearance as the experimental group twice a day, 500mg per time. Receives: Other: Placebo |
| Baseline control | No intervention | Recruit 100 healthy individual volunteers aged 18 - 70 years old (20 volunteers in the age range of 18 - 30, 20 in 30 - 40, 20 in 40 - 50, 20 in 50 - 60, and 20 in 60 - 70, with an equal number of males and females in each age group) as the baseline control for age-related changes. This group will not receive any intervention. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Evaluate the effectiveness of vitamin C in intervening in aging
DNA methylation composite clock
Measured: 12 months
Secondary outcomes (11)
blood cell transcriptomics
blood cell transcriptomics
Measured: 12 months
proteomics
proteomics in blood
Measured: 12 months
metabolomics
metabolomics in blood
Measured: 12 months
gut microbiome
gut microbiome in fecal sample
Measured: 12 months
Cognitive function
Trail Making Test
Measured: 1 year
Physical Fitness Test
The score of Purdue pegboard test, Grip Strength Test，and Single Leg Stand Test with Eyes Closed
Measured: 1 year
Maximal oxygen consumption
Maximal oxygen consumption
Measured: 1 year
Motor Function
Hamilton Anxiety Scale
Measured: 1 year
muscle mass
By means of measurement of lean body mass using dual-energy X-ray absorptiometry (DXA)
Measured: 1 year
Cardiovascular disease
Standardised composite score (Z score) of systolic blood pressure, LDL cholesterol, and body-mass index (BMI).
Measured: 1 year
Vitamin C level
Vitamin C level in serum
Measured: 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted27 Jan 2025
- Study start2 Apr 2025
- Primary completion30 Jan 2026 (estimated)
- Study completion30 Jan 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for AgeingStudies of the same condition, open and under way.
- More trials run by Peking University Third HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind
- Who is masked
- Participant, Care provider, Outcomes assessor
- Enrolment
- 400 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Peking University Third Hospital
- Sponsor type
- University, hospital or other
- Collaborators
- The First Affiliated Hospital of Nanchang University, People's Hospital of Quzhou
- Responsible party
- Principal investigator, Jie Qiao, Peking University Third Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06794255
- Sponsor's protocol ID
- M2024651
- Other IDs
- 88888888
- Acronym
- VitC-Aging
- Status last verified
- Jan 2025
- First submitted
- 10 Jan 2025
- Last updated
- 27 Jun 2025
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: I have decided not to share the IPD from this study due to concerns about participant privacy and confidentiality. Our study will include multiple-omic data, including genomic data. There are legal and ethical considerations that restrict the sharing of sensitive health information and genetic information without consent. Furthermore, the resources required to prepare and manage the data for external sharing are currently beyond our capacity. Therefore, to ensure the protection of our participants and comply with ethical standards, we have opted not to share the IPD at this time.
Study at a glance
From the registry record, last updated by the sponsor on 27 Jun 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Randomized Controlled Trial on Vitamin C Supolementation for HealthRegulation in Middle-Aged and Elderly Adults
- ClinicalTrials.gov ID
- NCT06794255
- Acronym / sponsor ID
- VitC-Aging / M2024651
- Conditions
- Ageing
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 400 participants (estimated)
- Lead sponsor
- Peking University Third HospitalUniversity, hospital or other
- Collaborators
- The First Affiliated Hospital of Nanchang University, People's Hospital of Quzhou
- Study start
- 2 Apr 2025 (actual)
- Primary completion
- 30 Jan 2026 (estimated)
- Study completion
- 30 Jan 2027 (estimated)
- First posted
- 27 Jan 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this clinical trial is to understand whether oral vitamin C can help delay the aging of middle-aged and elderly individuals, search for sensitive biomarkers of human aging, and provide new paradigms and scientific guidance for aging intervention with small molecule drugs. The main questions it aims to answer are as follows:
- Can oral vitamin C effectively improve the aging-related indicators?
- What is the safety of participants when taking vitamin C supplements?
Researchers will compare vitamin C with a placebo to observe whether vitamin C is effective in intervening in the aging of middle-aged and elderly individuals. Participants need to:
- Take 2 tablets (250mg/tablet) of vitamin C or placebo after breakfast and dinner every day for 12 consecutive months;
- Go to the designated place for a face-to-face follow-up every 6 months and receive a telephone follow-up every 2 months, and pick up subsequent drugs during the follow-up;
- Honestly inform the medication situation during each follow-up;
- Report any discomfort or adverse reactions that occur during the treatment process to the researchers;
- Fill in a questionnaire about their own health status during each follow-up;
- After 6 months and 12 months of intervention, conduct a comprehensive health examination as required, including blood tests and other items.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, care provider, outcomes assessor)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Vitamin C | Experimental | Dietary Supplement: Vitamin CParticipants will take the synthetic vitamin C twice a day, 500mg per time |
| Placebo | Placebo comparator | Other: PlaceboParticipants will take tablets with the same texture, flavor, and appearance as the experimental group twice a day, 500mg per time. |
| Baseline control | No intervention | –Recruit 100 healthy individual volunteers aged 18 - 70 years old (20 volunteers in the age range of 18 - 30, 20 in 30 - 40, 20 in 40 - 50, 20 in 50 - 60, and 20 in 60 - 70, with an equal number of males and females in each age group) as the baseline control for age-related changes. This group will not receive any intervention. |
Who may qualify
- Ages
- 18 to 70 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Age: 55-65 years (for the experimental and control groups) or 18-70 years (for the baseline control group assessing aging changes).
- Health Status: Deemed to be in good health based on medical evaluation, including medical history, physical examination, laboratory tests, and cardiac monitoring.
- Weight: BMI within the range of 18.5-28 kg/m².
- Informed Consent: Capable of signing the informed consent form and complying with the requirements and restrictions outlined in the study protocol.
Key exclusion criteria (9 listed)
- Disease Status:Uncontrolled medical conditions or any disease that, in the investigator's opinion, may pose an inappropriate risk or contraindication or interfere with the study's objectives, conduct, or evaluation.Severe chronic or acute diseases (e.g., cancer, heart failure, renal insufficiency, COPD, diabetes, active liver disease, metabolic acidosis, poorly controlled hypertension, epilepsy, recent cardiovascular events, inflammatory bowel disease, neurological disorders, infectious diseases, severe autoimmune diseases, etc.).
- Weight: BMI < 18.5 or BMI > 28.
- Substance/Alcohol Abuse: Ongoing alcohol or drug abuse, or excessive alcohol consumption.
- Medical History: History of gastrointestinal diseases, hyperuricemia, kidney or urinary tract stones, glucose-6-phosphate dehydrogenase deficiency, or paroxysmal nocturnal hemoglobinuria.
- Allergy: Allergy to vitamin C or any component of its formulation.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Vitamin CParticipants swallow synthetic vitamin C tablets 500mg with water, twice a day. | Dietary supplement | Vitamin C |
| PlaceboParticipants swallow tablets with the same texture, flavor, and appearance as the experimental group 500mg with water, twice a day. | Other | Placebo |
Primary outcome
Evaluate the effectiveness of vitamin C in intervening in aging
Time frame: 12 months
DNA methylation composite clock
11 secondary outcomes
blood cell transcriptomics
Time frame: 12 months
proteomics
Time frame: 12 months
metabolomics
Time frame: 12 months
gut microbiome
Time frame: 12 months
Cognitive function
Time frame: 1 year
Physical Fitness Test
Time frame: 1 year
Maximal oxygen consumption
Time frame: 1 year
Motor Function
Time frame: 1 year
muscle mass
Time frame: 1 year
Cardiovascular disease
Time frame: 1 year
Vitamin C level
Time frame: 1 year
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 27 Jun 2025.
- Individual participant dataSharing planned: No. I have decided not to share the IPD from this study due to concerns about participant privacy and confidentiality. Our study will include multiple-omic data, including genomic data. There are legal and ethical considerations that restrict the sharing of sensitive health information and genetic information without consent. Furthermore, the resources required to prepare and manage the data for external sharing are currently beyond our capacity. Therefore, to ensure the protection of our participants and comply with ethical standards, we have opted not to share the IPD at this time.
Related trials for Ageing
RecruitingPhase 2
Neuroplasticity Enhancement From Cognitive Training Reinforced by Psilocybin
Alzheimer's Disease
Recruiting
Colon-delivered Riboflavin and Gut Microbiota Composition
Microbiome Dysbiosis, Gut Health
RecruitingPhase 2
Metformin as an add-on or Monotherapy in Treatment of Aging People With Multiple Sclerosis (MS)
Multiple Sclerosis
Not yet recruitingPhase 2
Validation & Intervention Testing for Aging, Longevity and Healthspan
Aging, Functional Decline
RecruitingObservational study
Effects of Obesity on Physical Abilities and Daily Living Activities in Elderly Adults
Obesity, Sarcopenic Obesity
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
3 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Vitamin C in people with Ageing, run by Peking University Third Hospital at 3 sites in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 27 Jun 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 3 sites in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Tian Tian (+8601082266355, tiantianpku@126.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Evaluate the effectiveness of vitamin C in intervening in aging (time frame: 12 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Jun 2025.